These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 29874073)
1. Myeloid Cell Leukemia 1 Inhibition: An in Silico Study Using Non-equilibrium Fast Double Annihilation Technology. Procacci P J Chem Theory Comput; 2018 Jul; 14(7):3890-3902. PubMed ID: 29874073 [TBL] [Abstract][Full Text] [Related]
2. Assessment of GAFF2 and OPLS-AA General Force Fields in Combination with the Water Models TIP3P, SPCE, and OPC3 for the Solvation Free Energy of Druglike Organic Molecules. Vassetti D; Pagliai M; Procacci P J Chem Theory Comput; 2019 Mar; 15(3):1983-1995. PubMed ID: 30694667 [TBL] [Abstract][Full Text] [Related]
3. Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates. Drennen B; Scheenstra JA; Yap JL; Chen L; Lanning ME; Roth BM; Wilder PT; Fletcher S ChemMedChem; 2016 Apr; 11(8):827-33. PubMed ID: 26844930 [TBL] [Abstract][Full Text] [Related]
4. II. Dissociation free energies in drug-receptor systems via nonequilibrium alchemical simulations: application to the FK506-related immunophilin ligands. Nerattini F; Chelli R; Procacci P Phys Chem Chem Phys; 2016 Jun; 18(22):15005-18. PubMed ID: 27193181 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening. Mady ASA; Liao C; Bajwa N; Kump KJ; Abulwerdi FA; Lev KL; Miao L; Grigsby SM; Perdih A; Stuckey JA; Du Y; Fu H; Nikolovska-Coleska Z Sci Rep; 2018 Jul; 8(1):10210. PubMed ID: 29976942 [TBL] [Abstract][Full Text] [Related]
6. SAMPL6 host-guest blind predictions using a non equilibrium alchemical approach. Procacci P; Guarrasi M; Guarnieri G J Comput Aided Mol Des; 2018 Oct; 32(10):965-982. PubMed ID: 30128927 [TBL] [Abstract][Full Text] [Related]
7. Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1. Beekman AM; Howell LA ChemMedChem; 2016 Apr; 11(8):802-13. PubMed ID: 26696548 [TBL] [Abstract][Full Text] [Related]
9. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800 [TBL] [Abstract][Full Text] [Related]
10. Prediction of Hot Spots at Myeloid Cell Leukemia-1-Inhibitor Interface Using Energy Estimation and Alanine Scanning Mutagenesis. Marimuthu P; Singaravelu K Biochemistry; 2018 Feb; 57(7):1249-1261. PubMed ID: 29345906 [TBL] [Abstract][Full Text] [Related]
11. Kröhnke pyridines: Rapid and facile access to Mcl-1 inhibitors. Conlon IL; Van Eker D; Abdelmalak S; Murphy WA; Bashir H; Sun M; Chauhan J; Varney KM; Godoy-Ruiz R; Wilder PT; Fletcher S Bioorg Med Chem Lett; 2018 Jun; 28(10):1949-1953. PubMed ID: 29705141 [TBL] [Abstract][Full Text] [Related]
13. OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules. Roos K; Wu C; Damm W; Reboul M; Stevenson JM; Lu C; Dahlgren MK; Mondal S; Chen W; Wang L; Abel R; Friesner RA; Harder ED J Chem Theory Comput; 2019 Mar; 15(3):1863-1874. PubMed ID: 30768902 [TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics study of segment peptides of Bax, Bim, and Mcl-1 BH3 domain of the apoptosis-regulating proteins bound to the anti-apoptotic Mcl-1 protein. Zhao RN; Fan S; Han JG; Liu G J Biomol Struct Dyn; 2015; 33(5):1067-81. PubMed ID: 24865469 [TBL] [Abstract][Full Text] [Related]
15. Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonance. Glantz-Gashai Y; Meirson T; Reuveni E; Samson AO Drug Des Devel Ther; 2017; 11():1803-1813. PubMed ID: 28684899 [TBL] [Abstract][Full Text] [Related]
16. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents. Wan Y; Dai N; Tang Z; Fang H Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973 [TBL] [Abstract][Full Text] [Related]
17. Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin. Zhao B; Sensintaffar J; Bian Z; Belmar J; Lee T; Olejniczak ET; Fesik SW Bioorg Med Chem; 2017 Jun; 25(12):3087-3092. PubMed ID: 28428041 [TBL] [Abstract][Full Text] [Related]
18. PrimaDORAC: A Free Web Interface for the Assignment of Partial Charges, Chemical Topology, and Bonded Parameters in Organic or Drug Molecules. Procacci P J Chem Inf Model; 2017 Jun; 57(6):1240-1245. PubMed ID: 28586207 [TBL] [Abstract][Full Text] [Related]
19. Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors. Luan S; Ge Q; Chen Y; Dai M; Yang J; Li K; Liu D; Zhao L Bioorg Med Chem Lett; 2017 May; 27(9):1943-1948. PubMed ID: 28343875 [TBL] [Abstract][Full Text] [Related]
20. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides. Modi V; Sankararamakrishnan R J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]